Avalo Therapeutics (NASDAQ:AVTX) Price Target Cut to $10.00 by Analysts at BTIG Research

Avalo Therapeutics (NASDAQ:AVTX) had its price objective dropped by equities research analysts at BTIG Research to $10.00 in a research report issued to clients and investors on Friday, MarketBeat reports. The brokerage presently has a “buy” rating on the stock. BTIG Research‘s price objective points to a potential upside of 46.18% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on AVTX. Wall Street Zen downgraded shares of Avalo Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, September 12th. Guggenheim reaffirmed a “neutral” rating on shares of Avalo Therapeutics in a research report on Friday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Avalo Therapeutics in a research report on Wednesday, September 16th. Weiss Ratings raised shares of Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, Leerink Partners began coverage on shares of Avalo Therapeutics in a research report on Monday, July 6th. They set an “outperform” rating and a $38.00 price objective for the company. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.10.

Avalo Therapeutics Stock Performance

Shares of Avalo Therapeutics stock traded down $0.61 during trading on Friday, reaching $6.84. The company had a trading volume of 2,397,378 shares, compared to its average volume of 1,276,664. The company has a market cap of $366.88 million, a price-to-earnings ratio of -1.57 and a beta of 0.68. The firm’s fifty day moving average is $16.30 and its 200-day moving average is $16.67. Avalo Therapeutics has a fifty-two week low of $6.53 and a fifty-two week high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX) last issued its earnings results on Thursday, August 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). On average, research analysts anticipate that Avalo Therapeutics will post -2.95 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Christopher Sullivan sold 12,394 shares of the stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $16.33, for a total value of $202,394.02. Following the completion of the transaction, the chief financial officer directly owned 39,900 shares in the company, valued at $651,567. This trade represents a 23.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 24,258 shares of company stock valued at $415,434. 4.46% of the stock is currently owned by corporate insiders.

Institutional Trading of Avalo Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Seven Fleet Capital Management LP lifted its stake in Avalo Therapeutics by 34.3% during the second quarter. Seven Fleet Capital Management LP now owns 770,765 shares of the company’s stock valued at $14,244,000 after purchasing an additional 196,882 shares during the last quarter. Wellington Management Group LLP acquired a new stake in Avalo Therapeutics during the second quarter valued at approximately $1,945,000. Renaissance Technologies LLC lifted its stake in Avalo Therapeutics by 556.4% during the first quarter. Renaissance Technologies LLC now owns 120,114 shares of the company’s stock valued at $1,793,000 after purchasing an additional 101,814 shares during the last quarter. DV Trading LLC acquired a new stake in Avalo Therapeutics during the first quarter valued at approximately $5,376,000. Finally, Sei Investments Co. purchased a new stake in shares of Avalo Therapeutics in the 1st quarter valued at approximately $849,000. 87.06% of the stock is owned by institutional investors and hedge funds.

Avalo Therapeutics News Summary

Here are the key news stories impacting Avalo Therapeutics this week:

• Positive Sentiment: Wedbush maintained an Outperform rating and set a $22 price target. Although the target was reduced from $34, it still implies substantial potential upside from current trading levels, signaling that the firm views the recent selloff as overdone. Wedbush Adjusts Avalo Therapeutics Price Target
• Positive Sentiment: BTIG Research reduced its price target to $10 but retained a Buy rating, indicating that the analyst still sees value despite lowering its valuation assumptions.
• Neutral Sentiment: Guggenheim reaffirmed its Neutral rating, while HC Wainwright shifted from Buy to Neutral. The changes reflect a more cautious analyst outlook, but neither firm issued a Sell rating.
• Neutral Sentiment: Trading in AVTX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating unusually rapid volatility and triggering an exchange-mandated pause.
• Negative Sentiment: AbbVie’s favorable Phase III HS results weighed on Avalo shares by raising concerns that a competing therapy could reduce Avalo’s future market opportunity or weaken the commercial outlook for its pipeline. AbbVie Phase III Data Subdue Avalo Shares
• Negative Sentiment: The broad reductions in analyst price targets—including Wedbush’s cut from $34 to $22 and BTIG’s move to $10—suggest that expectations for Avalo’s near-term valuation have been reset lower, even though some analysts remain bullish.

About Avalo Therapeutics

Avalo Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research and development programs are intended to address conditions with significant unmet medical needs.

Avalo’s lead product candidate is AVTX-009, a fully human monoclonal antibody designed to inhibit interleukin-1 beta, an inflammatory cytokine involved in several immune-related disorders. The candidate is being evaluated for potential treatment of hidradenitis suppurativa, a chronic inflammatory skin disease, and other inflammatory conditions.

The company was formerly known as Cerecor Inc and adopted the Avalo Therapeutics name in 2021.